Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | OPRK1 | P41145 | 2/20 | 0.35 |
| ▸ | TERT | O14746 | 4/20 | 0.33 |
| ▸ | LNPEP | Q9UIQ6 | 1/20 | 0.33 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.33 |
| ▸ | L3MBTL1 | Q9Y468 | 3/20 | 0.33 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.33 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.33 |
| ▸ | AVPR1B | P47901 | 2/20 | 0.33 |
| ▸ | MEN1 | O00255 | 1/20 | 0.32 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.32 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.32 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.32 |
| ▸ | MCL1 | Q07820 | 1/20 | 0.31 |
| ▸ | MAPT | P10636 | 1/20 | 0.31 |
| ▸ | CCR2 | P41597 | 3/20 | 0.31 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.31 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.31 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.31 |
| ▸ | HTR2A | P28223 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23248918 | 0.97 | OPRK1 (0.33) | OPRK1KDM4EL3MBTL1ALDH1A1TDP1 | |
| SCHEMBL24555664 | 0.92 | LNPEP (0.32) | OPRK1TERTLNPEPALDH1A1AVPR1B | |
| SCHEMBL23250150 | 0.91 | OPRK1 (0.32) | OPRK1KDM4EL3MBTL1ALDH1A1TDP1 | |
| SCHEMBL25819424 | 0.90 | POLB (0.36) | ALDH1A1AVPR1BMEN1KMT2ASMN1; SMN2 | |
| SCHEMBL23256342 | 0.89 | TERT (0.31) | OPRK1TERTKDM4EALDH1A1AVPR1B | |
| SCHEMBL29863481 | 0.89 | OPRK1 (0.32) | OPRK1KDM4EALDH1A1 | |
| SCHEMBL23255920 | 0.89 | KDM4E (0.33) | OPRK1LNPEPKDM4EL3MBTL1ALDH1A1 | |
| SCHEMBL23255954 | 0.88 | OPRK1 (0.31) | OPRK1KDM4EALDH1A1 | |
| SCHEMBL31629365 | 0.87 | SMN1; SMN2 (0.30) | SMN1; SMN2 | |
| SCHEMBL23256514 | 0.87 | EPHX2 (0.33) | AVPR1BSMN1; SMN2HTR2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11370773-B1 | Inhibiting human integrin (alpha-4) (beta-7) | MORPHIC THERAPEUTIC, INC. (US) | 2022-06-28 | — | — | US | disclosed |
| WO-2021076890-A1 | INHIBITING HUMAN INTEGRIN α4β7 | MORPHIC THERAPEUTIC, INC. (US) | 2021-04-22 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11370773-B1 | Inhibiting human integrin (alpha-4) (beta-7) | ITGB7, ITGB4, ITGA4 | OPRK1 1286/4885TERT 3053/4885LNPEP 2898/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.